Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

157 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinical Presentation of COVID-19 and Antibody Responses in Bangladeshi Patients Infected with the Delta or Omicron Variants of SARS-CoV-2.
Ghosh AK, Landt O, Yeasmin M, Sharif M, Ratul RH, Molla MA, Nafisa T, Mosaddeque MB, Hosen N, Bulbul MRH, Mamunur R, Islam A, Shakil SS, Kaiser M, Amin MR, Lytton SD. Ghosh AK, et al. Among authors: hosen n. Vaccines (Basel). 2022 Nov 18;10(11):1959. doi: 10.3390/vaccines10111959. Vaccines (Basel). 2022. PMID: 36423054 Free PMC article.
The lymphocyte/monocyte ratio predicts the efficacy of isatuximab plus pomalidomide in multiple myeloma patients.
Shimazu Y, Kanda J, Onda Y, Fuchida SI, Ohta K, Shimura Y, Kosugi S, Yamamura R, Matsuda M, Hanamoto H, Adachi Y, Anzai N, Hotta M, Fukushima K, Yagi H, Yoshihara S, Tanaka Y, Takakuwa T, Tanaka H, Shibayama H, Uoshima N, Hosen N, Ito T, Shimazaki C, Matsumura I, Kuroda J, Takaori-Kondo A, Hino M. Shimazu Y, et al. Among authors: hosen n. Cancer Immunol Immunother. 2024 May 17;73(7):135. doi: 10.1007/s00262-024-03711-8. Cancer Immunol Immunother. 2024. PMID: 38758239 Free PMC article.
Efficacy of elotuzumab for multiple myeloma deteriorates after daratumumab: a multicenter retrospective study.
Nakamura N, Arima N, Takakuwa T, Yoshioka S, Imada K, Fukushima K, Hotta M, Fuchida SI, Kanda J, Uoshima N, Shimura Y, Tanaka H, Ohta K, Kosugi S, Yagi H, Yoshihara S, Yamamura R, Adachi Y, Hanamoto H, Shibayama H, Hosen N, Ito T, Shimazaki C, Takaori-Kondo A, Kuroda J, Matsumura I, Hino M; Kansai Myeloma Forum. Nakamura N, et al. Among authors: hosen n. Ann Hematol. 2024 Mar 16. doi: 10.1007/s00277-024-05705-z. Online ahead of print. Ann Hematol. 2024. PMID: 38492020
[Sequential therapy with inotuzumab ozogamicin followed by CAR T-cell therapy for Philadelphia chromosome-negative acute lymphoblastic leukemia].
Mizutani Y, Kusakabe S, Fukushima K, Murakami H, Hamada M, Hasegawa C, Mizuta E, Yamaguchi Y, Nakai R, Kurashige R, Hino A, Ueda T, Fujita J, Miyamura T, Hosen N. Mizutani Y, et al. Among authors: hosen n. Rinsho Ketsueki. 2024;65(2):78-83. doi: 10.11406/rinketsu.65.78. Rinsho Ketsueki. 2024. PMID: 38448002 Japanese.
Differentiating Between Epstein-Barr Virus-positive Lymphoid Neoplasm Relapse and Post-transplant Lymphoproliferative Disorder After Sex-mismatched Hematopoietic Stem Cell Transplantation.
Kurashige R, Kurashige M, Okada Y, Higuchi K, Yuda S, Hino A, Miyamura T, Ichii M, Fukushima K, Honma K, Takeuchi M, Yokota T, Ishikawa J, Sawada A, Shibayama H, Hosen N, Morii E. Kurashige R, et al. Among authors: hosen n. Am J Surg Pathol. 2024 Apr 1;48(4):395-405. doi: 10.1097/PAS.0000000000002183. Epub 2024 Jan 30. Am J Surg Pathol. 2024. PMID: 38287877
157 results